Mirabegron

Independent reference data for Mirabegron (CAS 223673-61-8), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Physicochemical values on record

Documented uses on record

Mirabegron is indicated for the treatment of overactive bladder (OAB) - with symptoms of urge urinary incontinence, urgency, and urinary frequency - either alone or in combination with [solifenacin]. It is also indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 3 years of age and older and weighing 35kg or more.Mirabegron is a beta-3 adrenergic agonist that is used for treatment of overactive bladder syndrome. Mirabegron has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.

Synonyms and trade names

Mirabegron; 223673-61-8; Myrbetriq; Betanis; Betmiga; YM-178; YM178; MVR3JL3B2V; 2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide; CHEBI:65349; DTXSID101021648; 2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide; 2-(2-Aminothiazol-4-yl)-4'-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)acetanilide; 4-Thiazoleacetamide, 2-amino-N-(4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)-; 2-(2-AMINO-1,3-THIAZOL-4-YL)-N-(4-(2-(((2R)-2-HYDROXY-2-PHENYLETHYL)AMINO)ETHYL)PHENYL)ACETAMIDE; mirabegronum

GHS hazard classification

Reported hazard statements	H302 (72.7%), H317 (54.5%), H319 (27.3%), H361 (45.5%), H373 (45.5%), H410 (36.4%)

H302 (72.7%): Harmful if swallowed [Warning Acute toxicity, oral]

H317 (54.5%): May cause an allergic skin reaction [Warning Sensitization, Skin]

What the public record says

Mirabegron · CAS 223673-61-8 · C21H24N4O2S. UNII MVR3JL3B2V. European Pharmacopoeia monograph. Solubility: 0.082.

Source: PubChem / Wikidata; the batch COA governs where values differ.